For the third straight year Lumenis wins an award recognizing outstanding medical companies and technologies.
Ms. Moore has partnered with Lumenis as a brand ambassador for OptiLight to tell her story and empower others.
After suffering for years with dry, itchy, burning eyes, Ms. Moore learned her problem was dry eye disease—a condition that affects millions of people. After undergoing treatment with OptiLight, Ms. Moore’s quality of life greatly improved.
OptiLight is a revolutionary, patented treatment that is the first and only light-based therapy for dry eye disease.
Lumenis Ltd., the world’s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).
Optima IPL Receives CFDA Mark Approval for Treatment of Dry Eye Disease
Now this exciting technology is available to practitioners in China for DED